Latest News
Rigetti Computing's Strong Cash Position Offsets Steep Revenue Multiple
Rigetti Computing shares rose 7.7% since Friday, outperforming quantum peers, as its $569M cash reserve highlights a 290x sales multiple.
Tesla Q2 earnings miss on profit, beat on cash flow, shares dip
Tesla's Q2 adjusted earnings of $0.33 per share missed the $0.55 consensus, but free cash flow of -$1.09B was better than the expected -$3.25B. Shares slipped 2.6% in after-hours trading.
IBM Trims 2026 Revenue Forecast, Puts Pressure on H2 Cash Flow
IBM cut its 2026 revenue growth forecast to 4%-5% and held its cash flow target, raising the bar for H2. Q2 revenue of $17.16B fell short of analyst expectations.
Alphabet Cloud Drives Profit Surge as Free Cash Flow Turns Negative
Alphabet's cloud division powered 63% of operating profit growth, but free cash flow turned negative at -$5.9B due to soaring capital expenditures.
Zhibao Surges 57% on 3,500 Bitcoin PIPE Deal, Dilution Details Unclear
Zhibao Technology (ZBAO) shares surged 57% to $0.285 after a non-binding PIPE deal involving 3,500 bitcoin, valued at $230.2 million. Key details on pricing and dilution are still missing.
Advanced Biomed Surges 74.6% After Terminating $25M Equity Facility
Shares of Advanced Biomed (ADVB) jumped 74.6% after the company terminated a $25 million equity facility, removing overhang of potential dilution.
Knightscope Stock Jumps 46% on Q2 Preliminary Revenue Beat
Knightscope shares rose 46% to $2.09 after preliminary Q2 revenue of $9 million, more than three times last year's figure, though slightly below Q1 pro forma levels.
Bank of America Stock Nears 52-Week High, Reducing Buyback Efficiency
Bank of America shares rose 0.6% to $61.57, approaching their 52-week high, which reduces the effectiveness of buyback programs as each dollar repurchases fewer shares.
NIO Stock Drops as Chip Unit GeniTech Stake Valued at $763M
NIO shares declined 2.5% after its remaining 62.7% stake in chip subsidiary GeniTech was valued at approximately $763 million, representing 7.8% of the company's market capitalization.
Arrowhead Surges 23% on Positive Plozasiran Phase 3 Data
Arrowhead Pharmaceuticals (ARWR) shares surged 23% after Plozasiran Phase 3 data showed 79-81% median triglyceride reduction and 78% fewer pancreatitis events.